Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05463263 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
A Phase 1 study of Lymphoma, B-Cell and Lymphoma, T-Cell, sponsored by Step Pharma, SAS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 15
- Study locations
NCT05463263 is a Phase 1 study of Lymphoma, B-Cell and Lymphoma, T-Cell that is actively recruiting participants, run by Step Pharma, SAS. The registered enrollment target is 180 participants, roughly in line with the 196-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target. The trial reports 15 study locations across 4 states.
The verdict
NCT05463263, a Phase 1 study of Lymphoma, B-Cell and Lymphoma, T-Cell, is actively recruiting participants, sponsored by Step Pharma, SAS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 15
- Study locations
Study Summary
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
Conditions Studied
Interventions
- DRUG STP938
Study Locations (15)
Other
- The Centre Léon Bérard - Lyon
- Institut Paoli Calmettes - Marseille
- CHU de Nantes - Nantes
- Hôpital Saint-Louis - Paris
- Institut Gustave Roussy - Villejuif
- University Hospitals of Leicester NHS Trust - Leicester
- Imperial College / Clinical Trials Unit, Hammersmith Hospital - London
- The Christie - Manchester
- Nottingham City Hospital - Nottingham
- Churchill Hospital - Oxford
- Derriford Hospital - Plymouth
- The Royal Marsden - Sutton
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Florida Cancer Specialists - Sarasota
New York
- Memorial Sloan Kettering - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05463263
The ClinicalTrials.gov registry entry for NCT05463263 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 196-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target. The listed sponsor is Step Pharma, SAS, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma, B-Cell appearing as the primary indexed condition, and to 1 intervention - of which STP938 is the first listed.
NCT05463263 reports 15 study locations spanning 4 distinct geographic areas - top geographies include Other, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT05463263 about?
NCT05463263 is a clinical study titled "A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas". The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
What is the current status of trial NCT05463263?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2022-08-03. Estimated completion is 2025-12.
What conditions does trial NCT05463263 study?
This clinical trial studies the following conditions: Lymphoma, B-Cell, Lymphoma, T-Cell.
What interventions are being tested in trial NCT05463263?
The interventions under investigation include: STP938 (DRUG).
Who is sponsoring clinical trial NCT05463263?
This trial is sponsored by Step Pharma, SAS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05463263 being conducted?
This trial has 15 study locations across Colorado, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
RECRUITING · Phase 1
-
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
RECRUITING · Phase 1
-
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.